{"nctId":"NCT03358147","briefTitle":"Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma","startDateStruct":{"date":"2017-12-13","type":"ACTUAL"},"conditions":["Asthma"],"count":1077,"armGroups":[{"label":"GP MDI 28.8 μg","type":"EXPERIMENTAL","interventionNames":["Drug: GP MDI 28.8 μg"]},{"label":"GP MDI 14.4 μg","type":"EXPERIMENTAL","interventionNames":["Drug: GP MDI 14.4 μg"]},{"label":"GP MDI 7.2 μg","type":"EXPERIMENTAL","interventionNames":["Drug: GP MDI 7.2 μg"]},{"label":"Placebo MDI","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo MDI"]},{"label":"Spiriva Respimat 2.5 μg","type":"OTHER","interventionNames":["Drug: Spiriva Respimat 2.5 μg"]}],"interventions":[{"name":"GP MDI 28.8 μg","otherNames":["GP"]},{"name":"GP MDI 14.4 μg","otherNames":["GP"]},{"name":"GP MDI 7.2 μg","otherNames":["GP"]},{"name":"Placebo MDI","otherNames":["Placebo"]},{"name":"Spiriva Respimat 2.5 μg","otherNames":["Spiriva Respimat"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have a documented history of physician-diagnosed asthma\n* Require inhaled asthma maintenance therapy: has been regularly using an ICS/LABA on a stable regimen for at least 4 weeks\n* Documented reversibility to albuterol\n* A pre-bronchodilator FEV1 \\>40% and \\<85% of predicted normal value for subjects 18 to 80 years of age or \\>40% and \\<90% of predicted for subjects 12 to \\<18 years of age\n* Demonstrate acceptable spirometry performance\n* Willing and, in the opinion of the Investigator, able to adjust current asthma therapy, as required by the protocol\n* Compliance: must be willing to remain at the study center as required per protocol to complete all visit assessments\n\nExclusion Criteria:\n\n* Oral corticosteroid use (any dose) within 4 weeks\n* Current smokers, former smokers with \\>10 pack-years history, or former smokers who stopped smoking \\<6 months (including all forms of tobacco, e-cigarettes, and marijuana)\n* Life-threatening asthma as defined as a history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma-related syncopal episode(s)\n* Completed treatment for lower respiratory infection or asthma exacerbation within 4 weeks\n* Hospitalizations for asthma within 3 months\n* Historical or current evidence of a clinically significant disease\n* Cancer not in complete remission for at least 5 years\n* Treatment with investigational study drug (or device) in another clinical study within the last 30 days or 5 half-lives, whichever is longer\n* Previously randomized in any PT001 study","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","maximumAge":"80 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 to 4 Hours (AUC0-4)","description":"Change from baseline in forced expiratory volume in 1 second (FEV1) area under the curve from 0 to 4 hours (AUC0-4)AUC was normalized for length of follow up (e.g. typically 4 hours).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.294","spread":null},{"groupId":"OG001","value":"0.284","spread":null},{"groupId":"OG002","value":"0.308","spread":null},{"groupId":"OG003","value":"0.240","spread":null},{"groupId":"OG004","value":"0.347","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Morning Pre-dose Trough FEV1","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.142","spread":null},{"groupId":"OG001","value":"0.108","spread":null},{"groupId":"OG002","value":"0.142","spread":null},{"groupId":"OG003","value":"0.129","spread":null},{"groupId":"OG004","value":"0.150","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Moderate to Severe Asthma Exacerbations","description":"Rate of moderate to severe Asthma exacerbations (A deterioration of asthma requiring a new or increased dose of ICS for at least 3 days) or severe Asthma exacerbation (Use of systemic corticosteroids (tablets, suspension, or injection) for at least 3 days OR a hospitalization or ER visit because of asthma)","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.43","spread":"0.078"},{"groupId":"OG001","value":"0.44","spread":"0.080"},{"groupId":"OG002","value":"0.41","spread":"0.076"},{"groupId":"OG003","value":"0.55","spread":"0.092"},{"groupId":"OG004","value":"0.50","spread":"0.123"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in ACQ-7 (Asthma Control Questionnaire)","description":"ACQ-7: The ACQ, comprising 7 questions, is completed in the clinic and requires subjects to recall their experiences during the previous week (7 days) prior to the study visit. The ACQ-5 measures 5 symptoms (woken at night by symptoms, wake in the morning with symptoms, limitation of daily activities, shortness of breath, and wheeze); the ACQ-6 is these symptom measurements plus daily rescue medication use as recalled by the subject; and the ACQ 7 is the ACQ 6 plus airway caliber as measured by pre-bronchodilator FEV1 percent predicted. Each question is scored on a 7-point scale (generally, 0=no impairment, 6=maximum impairment), the questions are equally weighted, and the ACQ score is the mean of the item responses and therefore ranges from 0 (totally controlled) to 6 (severely uncontrolled.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.78","spread":null},{"groupId":"OG001","value":"-0.73","spread":null},{"groupId":"OG002","value":"-0.90","spread":null},{"groupId":"OG003","value":"-0.80","spread":null},{"groupId":"OG004","value":"-0.90","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in ACQ-5 (Asthma Control Questionnaire)","description":"ACQ-5:The ACQ-5 measures 5 symptoms (woken at night by symptoms, wake in the morning with symptoms, limitation of daily activities, shortness of breath, and wheeze). Each question is scored on a 7-point scale (generally, 0=no impairment, 6=maximum impairment), the questions are equally weighted, and the ACQ score is the mean of the item responses and therefore ranges from 0 (totally controlled) to 6 (severely uncontrolled).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.87","spread":null},{"groupId":"OG001","value":"-0.80","spread":null},{"groupId":"OG002","value":"-1.02","spread":null},{"groupId":"OG003","value":"-0.93","spread":null},{"groupId":"OG004","value":"-1.03","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ +12)","description":"AQLQ +12 - Asthma Quality of Life Questionnaire The AQLQ +12 is a 32-item validated subject-administered questionnaire that was developed to measure the functional problems (physical, emotional, social and occupational) that are most troublesome to adults (≥18 years of age) and adolescents (12 to 17 years of age) with asthma. The 32 questions in the AQLQ +12 are in 4 domains (symptoms, activity limitation, emotional function, and environmental stimuli). All 4 domains contain standard specific questions relating to each domain. Subjects are asked to think about how they have been during the previous 2 weeks. Responses to each of the 32 questions are on a 7-point scale (7=no impairment to 1=severe impairment). The overall AQLQ +12 score is the mean of all 32 responses. Overall scores range from 1=severe impairment to 7=no impairment.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.89","spread":null},{"groupId":"OG001","value":"0.90","spread":null},{"groupId":"OG002","value":"1.02","spread":null},{"groupId":"OG003","value":"0.96","spread":null},{"groupId":"OG004","value":"1.04","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":235},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Sinusitis"]}}}